These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

566 related items for PubMed ID: 19480574

  • 1. High frequency of antiretroviral drug resistance among HIV-infected adults receiving first-line highly active antiretroviral therapy in N'Djamena, Chad.
    Koyalta D, Charpentier C, Beassamda J, Rey E, Si-Mohamed A, Djemadji-Oudjeil N, Bélec L.
    Clin Infect Dis; 2009 Jul 01; 49(1):155-9. PubMed ID: 19480574
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Genotypic resistance profiles in antiretroviral-naive HIV-1 infections before and after initiation of first-line HAART: impact of polymorphism on resistance to therapy.
    Sukasem C, Churdboonchart V, Sukeepaisarncharoen W, Piroj W, Inwisai T, Tiensuwan M, Chantratita W.
    Int J Antimicrob Agents; 2008 Mar 01; 31(3):277-81. PubMed ID: 18182278
    [Abstract] [Full Text] [Related]

  • 6. Virological response, HIV-1 drug resistance mutations and genetic diversity among patients on first-line antiretroviral therapy in N'Djamena, Chad: findings from a cross-sectional study.
    Adawaye C, Fokam J, Kamangu E, Alio HM, Chahad AM, Susin F, Moussa AM, Bertin TH, Tidjani A, Vaira D, Moutschen M.
    BMC Res Notes; 2017 Nov 10; 10(1):589. PubMed ID: 29126456
    [Abstract] [Full Text] [Related]

  • 7. Rapid selection and archiving of mutation E157Q in HIV-1 DNA during short-term low-level replication on a raltegravir-containing regimen.
    Ghosn J, Mazet AA, Avettand-Fenoel V, Peytavin G, Wirden M, Delfraissy JF, Chaix ML.
    J Antimicrob Chemother; 2009 Aug 10; 64(2):433-4. PubMed ID: 19457931
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Immunovirological outcomes and resistance patterns at 4 years of antiretroviral therapy use in HIV-infected patients in Cambodia.
    Pujades-Rodríguez M, Schramm B, Som L, Nerrienet E, Narom P, Chanchhaya N, Ferradini L, Balkan S.
    Trop Med Int Health; 2011 Feb 10; 16(2):205-13. PubMed ID: 21087376
    [Abstract] [Full Text] [Related]

  • 10. Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study.
    Cozzi-Lepri A, Phillips AN, Clotet B, Mocroft A, Ruiz L, Kirk O, Lazzarin A, Wiercinska-Drapalo A, Karlsson A, Lundgren JD, EuroSIDA Study Group.
    AIDS; 2008 Oct 18; 22(16):2187-98. PubMed ID: 18832882
    [Abstract] [Full Text] [Related]

  • 11. Both human immunodeficiency virus cellular DNA sequencing and plasma RNA sequencing are useful for detection of drug resistance mutations in blood samples from antiretroviral-drug-naive patients.
    Parisi SG, Boldrin C, Cruciani M, Nicolini G, Cerbaro I, Manfrin V, Dal Bello F, Franchin E, Franzetti M, Rossi MC, Cattelan AM, Romano L, Zazzi M, Andreoni M, Palù G.
    J Clin Microbiol; 2007 Jun 18; 45(6):1783-8. PubMed ID: 17442799
    [Abstract] [Full Text] [Related]

  • 12. Second-line antiretroviral treatment successfully resuppresses drug-resistant HIV-1 after first-line failure: prospective cohort in Sub-Saharan Africa.
    Sigaloff KC, Hamers RL, Wallis CL, Kityo C, Siwale M, Ive P, Botes ME, Mandaliya K, Wellington M, Osibogun A, Stevens WS, van Vugt M, Rinke de Wit TF, PharmAccess African Studies to Evaluate Resistance (PASER).
    J Infect Dis; 2012 Jun 18; 205(11):1739-44. PubMed ID: 22448003
    [Abstract] [Full Text] [Related]

  • 13. Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance.
    Sethi AK, Celentano DD, Gange SJ, Moore RD, Gallant JE.
    Clin Infect Dis; 2003 Oct 15; 37(8):1112-8. PubMed ID: 14523777
    [Abstract] [Full Text] [Related]

  • 14. Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients.
    Soria A, Porten K, Fampou-Toundji JC, Galli L, Mougnutou R, Buard V, Kfutwah A, Vessière A, Rousset D, Teck R, Calmy A, Ciaffi L, Lazzarin A, Gianotti N.
    Antivir Ther; 2009 Oct 15; 14(3):339-47. PubMed ID: 19474468
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Analysis of the diversity of the HIV-1 pol gene and drug resistance associated changes among drug-naïve patients in Burkina Faso.
    Tebit DM, Sangaré L, Tiba F, Saydou Y, Makamtse A, Somlare H, Bado G, Kouldiaty BG, Zabsonre I, Yameogo SL, Sathiandee K, Drabo JY, Kräusslich HG.
    J Med Virol; 2009 Oct 15; 81(10):1691-701. PubMed ID: 19697403
    [Abstract] [Full Text] [Related]

  • 18. Antiretroviral resistance.
    Geretti AM.
    J HIV Ther; 2006 Dec 15; 11(4):72-3. PubMed ID: 17578209
    [No Abstract] [Full Text] [Related]

  • 19. [Highly active initial therapy without resistance development. Even after 6 years still effective HIV therapy].
    MMW Fortschr Med; 2005 Apr 25; 147 Spec No 1():54-5. PubMed ID: 16385876
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.